%0 Journal Article
%T Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphoma.
%A Alencar AJ
%A Hirayama AV
%A Clé DV
%A Salvino MA
%A Perini G
%A Arrais C
%A Baiocchi O
%A Palma LC
%A Colturato I
%A Vaz J
%A Chiattone R
%A de Lima M
%A Filho JS
%A Nabhan S
%A Rocha V
%A Guerino-Cunha RL
%A Chiattone CS
%J Hematol Transfus Cell Ther
%V 43
%N 0
%D Nov 2021
%M 34794792
暂无%R 10.1016/j.htct.2021.09.003
%X The treatment and evolution of B-cell non-Hodgkin lymphoma (B-NHL) has undergone important changes in the last years with the emergence of targeted therapies, such as monoclonal antibodies, small molecules, antibody-drug conjugates, and bispecific antibodies. Nevertheless, a significant portion of patients remains refractory or relapsed (R/R) to the new therapeutic modalities, representing thus an unmet medical need. The use of CAR-T cells for the treatment of B-NHL patients has shown to be a promising therapy with impressive results in patients with R/R disease. The expectations are as high as the imminent approval of CAR-T cell therapy in Brazil, which it is expected to impact the prognosis of R/R B-NHL. The aim of this manuscript is to offer a consensus of specialists in the field of onco-hematology and cellular therapy, working in Brazil and United States, in order to discuss and offer recommendations in the present setting of the use of CAR-T cells for patients with B-NHL.